Immunotherapy for Alzheimer’s disease: targeting β-amyloid and tau

The complexity of Alzheimer’s disease (AD) pathogenesis has led to difficulties understanding the disease and, therefore, impacted the development of AD drugs. In this episode, AD specialists Philip Tipton, MD, Mayo Clinic, Jacksonville, FL; Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA; and Adam Fleisher, MD, MAS, Eli Lilly and Company, Indianapolis, IN, discuss the development of immunotherapeutic strategies for AD targeting β-amyloid and tau.